All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

BCL-2 inhibitors

BCL-2 inhibitors

Bcl-2 is a pro-survival oncogene that promotes leukemogenesis by blocking programmed cell death. Therefore, agents designed to disrupt the anti-apoptotic signaling pathway are considered for the treatment of hematological malignancies, including Bcl-2 inhibitors like venetoclax. Another subfamily of ‘BH3-only’ proteins induce apoptosis by binding to BCL-2. Agonists for pro-apoptotic proteins, like ‘BH3-only’ proteins, are in development.


All Interventions